Teva Pharmaceutical Industries Investor Presentation — February 2017

Document content

Teva Pharmaceutical Industries Ltd.

Full Year 2016 Results

February 13, 2017 Safe Harbor Statement under the U.S. Private

Securities Litigation Reform Act of 1995:

This presentation contains forward -looking statements, which are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future

results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward -looking statements . Important factors that could cause or contribute to

such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products ; competition for our specialty products, especially Copaxone® (which faces competition from orally -

administered alternatives and a generic version) ; our ability to realize the anticipated benefits of the acquisition of Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”), and the timing of realizing

such benefits ; our ability to fully and efficiently integrate Actavis Generics and to achieve the anticipated cost savings, synergies, business opportunities and growth prospects from the combination ; the fact that we are

now dependent to a much larger extent than previously on our generic pharmaceutical business ; our ability to develop and launch new generic products from the Actavis Generics pipeline on the anticipated timelines ;

potential restrictions on our ability to engage in additional transactions or incur additional indebtedness as a result of the substantial amount of debt we have incurred to finance the Actavis Generics acquisition ; the fact

that we will have significantly less cash on hand than prior to the consummation of the Actavis Generics acquisition, which could adversely affect our ability to grow ; our ability to achieve expected results from investments

in our pipeline of specialty and other products ; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions ; the extent to which any

manufacturing or quality control problems damage our reputation for quality production and require costly remediation ; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements ;

our exposure to currency fluctuations and restrictions as well as credit risks ; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty